Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

At the American Association for Cancer Research 101st Annual Meeting 2010, scientists and clinicians will present more than 6,300 abstracts dealing with innovative aspects of biology, technology and emerging therapies.

19 Apr 2010

Pharmacyclics to present on Btk and HDAC programs at AACR 2010

Pharmacyclics, Inc. today announced multiple presentations covering its Btk and HDAC programs at the American Association for Cancer Research 2010 Annual Meeting being held April 17-21 in Washington, DC.

16 Apr 2010

DNA modification can define early onset glioblastoma

A class of brain tumor that tends to emerge in younger patients but is less aggressive than others can be identified by examining DNA methylation of a specific set of genes, scientists at The University of Texas M. D. Anderson Cancer Center and colleagues with The Cancer Genome Atlas report today online at Cancer Cell.

16 Apr 2010

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Circadian Technologies Limited today released data demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth in a variety of different animal models (tumour xenografts) of human cancer.

16 Apr 2010

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

A study conducted by a collaborative team led by researchers from the University of Southern California (USC) may lead to better insight into the clinical outcome for some patients with a particularly aggressive type of brain cancer. The research may also provide a framework for development of targeted drug treatments.

16 Apr 2010

'Forgotten' cells in brain cancer

Glioblastoma is a guileful enemy. While most of the brain tumor can often be removed surgically, in virtually every case the tumor reappears. One reason for this is that sporadic, infiltrative tumor cells will remain in the brain even after most careful surgery. Researchers at the University of Bonn have now subjected these 'forgotten' cells to closer scrutiny for the first time.

13 Apr 2010

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Myriad Pharmaceuticals, Inc today announced that it has received a notice from Javelin Pharmaceuticals, Inc. of its intent to terminate the merger agreement between the two companies.

13 Apr 2010

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010.

12 Apr 2010

Brains on Bikes raises funds for brain cancer research and support

Anne Feeley, a 55-year-old mother and brain cancer survivor, began a 3,781-mile ride across the country today to raise money and awareness for brain cancer research and support.

12 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced plans to initiate a Phase 2 proof-of-concept clinical trial in the second half of 2010 to evaluate the effectiveness and safety of its oncology drug candidate bafetinib (formerly known as INNO-406) in patients with an advanced form of prostate cancer known as metastatic hormone-refractory prostate cancer.

7 Apr 2010

Oncologists to provide overview on new neuro-oncology guidelines

John Theurer Cancer Center at Hackensack University Medical Center will bring together top neuro-oncologists from around the country for an all day symposium to address new treatment updates and review management of complex cases across a broad array of neuro-oncology specialties.

6 Apr 2010

Notch pathway may be a good target for drug development, study says

Working with mice, Johns Hopkins scientists who tested drugs intended to halt growth of brain cancer stem cells -- a small population of cells within tumors that perpetuate cancer growth -- conclude that blocking these cells may be somewhat effective, but more than one targeted drug attack may be needed to get the job done.

3 Apr 2010

Brain stem cells in subventricular zone characterized by transcription factor Protein Tlx

The "cradle" of new neurons in the adult brain is well known. It is what is called the subventricular zone, a tissue structure lining the lateral ventricles. This is where neural or brain stem cells reside, which are responsible for generating new neurons if needed. For many years now, the subventricular zone has been suspected to be the origin of specific malignant brain tumors called gliomas, the most deadly type of which is glioblastoma.

2 Apr 2010

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

1 Apr 2010

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Gemin X Pharmaceuticals, a clinical stage biopharmaceutical company developing novel, targeted cancer therapeutics, today announced the completion of patient enrollment in a Phase 2 clinical trial of the Company's lead product candidate obatoclax (GX15-070) for the treatment of extensive-stage small cell lung cancer (SCLC). The trial is designed to evaluate the efficacy and safety of obatoclax, a novel pan Bcl-2 inhibitor, in combination with standard chemotherapy for the first-line treatment of patients with SCLC.

29 Mar 2010

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Erbitux® (cetuximab) can now be used in Japan in combination with chemotherapy in the 1st-line treatment for patients with epidermal growth factor receptor -expressing, curatively unresectable (inoperable), advanced or recurrent colorectal cancer carrying the KRAS wildtype gene.

29 Mar 2010

AVASTIN receives Health Canada approval for patients with GBM

Roche Canada announced today that Health Canada has approved AVASTIN(R) (bevacizumab), as a single agent, for the treatment of patients with glioblastoma multiforme, the most aggressive primary malignant brain tumour, after relapse or disease progression, following prior therapy.

26 Mar 2010

Tips offered in April 2010 issue of American Journal Of Pathology

A group led by Dr. Massimo Loda at the Dana Farber Cancer Institute, Boston, MA has generated a preclinical model of human prostate cancer that mimics the genetic and growth behavior of primary tumors. Their report can be found in the April 2010 issue of the American Journal of Pathology.

25 Mar 2010

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

ImmunoCellular Therapeutics announced today that Manish Singh, Ph.D., President and CEO, will be presenting at the Cancer Stem Cells Conference, a leading industry event, on Wednesday, March 24th at 2:00 p.m. eastern time.

25 Mar 2010

Glioblastoma News and Research

Further Reading

Radiolabeled hedgehog can differentiate stem-like cancer cells, identify aggressive tumors

Pharmacyclics to present on Btk and HDAC programs at AACR 2010

DNA modification can define early onset glioblastoma

Study: Circadian’s anti-cancer therapy reduces tumour growth in animal models

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

'Forgotten' cells in brain cancer

Javelin Pharmaceuticals intends to terminate Merger Agreement with Myriad Pharmaceuticals

Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Brains on Bikes raises funds for brain cancer research and support

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Cytrx to commence Phase 2 trial of bafetinib for advanced prostate cancer

Oncologists to provide overview on new neuro-oncology guidelines

Notch pathway may be a good target for drug development, study says

Brain stem cells in subventricular zone characterized by transcription factor Protein Tlx

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

Enrollment complete in Gemin X Pharmaceuticals' Phase 2 clinical trial of obatoclax for SCLC

Erbitux can now be used in Japan as 1st-line treatment for mCRC: Merck Serono

AVASTIN receives Health Canada approval for patients with GBM

Tips offered in April 2010 issue of American Journal Of Pathology

Clinical data of dendritic cell based vaccine to be presented at Cancer Stem Cells Conference

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News